82 related articles for article (PubMed ID: 6498851)
1. American cancer society Phase I trial of naturally produced beta-interferon.
Hawkins MJ; Krown SE; Borden EC; Krim M; Real FX; Edwards BS; Anderson SA; Cunningham-Rundles S; Oettgen HF
Cancer Res; 1984 Dec; 44(12 Pt 1):5934-8. PubMed ID: 6498851
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
6. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of natural human interferon beta in metastatic malignancy.
Bukowski RM; Sergi JS; Sharfman WJ; Budd GT; Murthy S; Barna B; Medendorp SV; Yen-Lieberman B; Gibson V; Bauer L
Cancer Res; 1991 Feb; 51(3):836-40. PubMed ID: 1988123
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha therapy of renal cancer.
Neidhart JA; Gagen MM; Young D; Tuttle R; Melink TJ; Ziccarrelli A; Kisner D
Cancer Res; 1984 Sep; 44(9):4140-3. PubMed ID: 6378379
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of partially pure gamma-interferon in cancer patients.
Gutterman JU; Rosenblum MG; Rios A; Fritsche HA; Quesada JR
Cancer Res; 1984 Sep; 44(9):4164-71. PubMed ID: 6430557
[TBL] [Abstract][Full Text] [Related]
12. [Gamma interferon therapy of cancer patients].
Kobayashi Y; Urabe A
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):804-9. PubMed ID: 3133983
[TBL] [Abstract][Full Text] [Related]
13. [Phase I-II study of recombinant interferon gamma].
Adachi K; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Nakada H; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1331-8. PubMed ID: 2988459
[TBL] [Abstract][Full Text] [Related]
14. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.
Vadhan-Raj S; Nathan CF; Sherwin SA; Oettgen HF; Krown SE
Cancer Treat Rep; 1986 May; 70(5):609-14. PubMed ID: 3085930
[TBL] [Abstract][Full Text] [Related]
16. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
Trump DL; Elson PJ; Borden EC; Harris JE; Tuttle RL; Whisnant JK; Oken MM; Carignan JR; Ruckdeschel JC; Davis TE
Cancer Treat Rep; 1987 Feb; 71(2):165-9. PubMed ID: 3802113
[TBL] [Abstract][Full Text] [Related]
17. [A cooperative phase I-II study of HLBI in patients with malignant tumors].
Kimura K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1324-31. PubMed ID: 6329104
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
19. Extended phase I study of human beta-interferon in human cancer.
Abdi EA; Kamitomo VJ; McPherson TA; Konrad MW; Inoue M; Tan YH
Clin Invest Med; 1986; 9(1):33-40. PubMed ID: 3955919
[TBL] [Abstract][Full Text] [Related]
20. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
